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: Improved process for the preparation of methyl 2-oxoindoline-6-ca

Improved process for the preparation of methyl 2-oxoindoline-6-carboxylate
Abstract:
The present invention provides a process for the preparation of methyl 2-oxoindoline6-carboxylate of formula-1, which is represented by the following structural formula:

Introduction:
Methyl 2-oxoindoline-6-carboxylate of formula-1 is key intermediate for the
preparation of Nintedanib esylate.
Nintedanib esylate is chemically known as 1H-Indole-6-carboxylic acid, 2,3-dihydro3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2oxo-,methyl ester, (3Z)-, ethanesulfonate (1:1).

Nintedanib is a small molecule tyrosine kinase inhibitor including the receptors
plateletderived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor
(FGFR) 1-3, and VEGFR 1-3. Nintedanib binds competitively to the ATP binding pocket of
these receptors and blocks the intracellular signalling. In addition, nintedanib inhibits Flt-3
(Fms-like tyrosine-protein kinase), Lck (lymphocyte-specific tyrosine-protein kinase), Lyn
(tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases.
Nintedanib inhibits the activation of FGFR and PDGFR signalling cascades which are
critically

involved

in

proliferation,

migration

and

differentiation

of

lung

fibroblasts/myofibroblasts, the hallmark cells in the pathology of idiopathic pulmonary
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fibrosis. The potential impact of VEGFR inhibition by nintedanib and the anti-angiogenic
activity of nintedanib on IPF pathology are currently not fully elucidated. In preclinical disease
models of lung fibrosis nintedanib exerts potent anti-fibrotic and anti-inflammatory activity.
Nintedanib inhibits proliferation, migration and fibroblast to myofibroblast transformation of
human lung fibroblasts from patients with IPF.
Nintedanib, marketed under the brand names Ofev and Vargatef, is a medication used
for the treatment of idiopathic pulmonary fibrosis (IPF) and along with other medications for
some types of non-small-cell lung cancer.
Nintedanib and its pharmaceutical acceptable salts was disclosed in US6762180 B1.
Disclosed herein the process for the preparation of methyl 2-oxoindoline-6-carboxylate
of formula-1, schematically as mentioned below:

The compound of formula-4 used in the present invention can be prepared from
any of the processes known in the art.
Experimental Section:
Example-1: Preparation of methyl 4-chloro-3-nitrobenzoate of Formula-3.
Methanol (500.0 ml) was added to 4-chloro-3-nitrobenzoic acid of formula-4 (100.0
gm) at 25-30ºC and stirred for 10 minutes. Thionyl chloride (30.0 gm) was slowly added to the
mixture at 25-30ºC and stirred for 40 minutes. Heated the mixture to 60-65ºC and stirred for 3
hours. Distilled off the mixture and co-distilled with isopropanol. Isopropanol (300.0 ml) was
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added to the obtained compound at 60-65ºC and stirred for 30 minutes. Cooled the mixture to
0-5ºC and stirred for 2 hours. Filtered the solid, washed with isopropanol and dried to get the
title compound. Yield: 102 gm.
Example-2: Preparation of dimethyl [4-(methoxycarbonyl)-2-nitrophenyl]propanedioate
of Formula-2.
Potassium tert-butoxide (52.0 gm) and dimethyl sulfoxide (150.0 ml) were added to
dimethyl malonate (52.0 gm) at 25-30ºC. Cooled the mixture to 20-25ºC and stirred for 2 hours.
Compound of formula-3 (50.0 gm) was slowly added to the mixture at 20-25ºC and stirred for
2 hours. Hydrochloric acid was added to the mixture at 20-25ºC. Sodium chloride (20.0 gm)
and methyl tert-butyl ether (250.0 ml) were added to the mixture at 25-30ºC and stirred for 10
minutes. Layers were separated and aqueous layer was extracted with methyl tert-butyl ether.
Distilled off the organic layer at below 50ºC to get the title compound. Yield: 53.0 gm.
Example-3: Preparation of methyl 2-oxoindoline-6-carboxylate of Formula-1.
Acetic acid (250.0 ml) was added to compound of formula-2 (50.0 gm) at 25-30ºC.
Hydrose (83.9 gm) and water (250.0 ml) were added to the mixture at 25-30ºC and stirred for
10 minutes. Heated the mixture to 120-125ºC and stirred for 2 hours. Cooled the mixture to 1520ºC. Ammonia (500.0 ml) was added to the mixture at 15-20ºC and stirred for 2 hours. Filtered
the solid, washed with water and dried to get the title compound. Yield: 22.0 gm.
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